Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mello Biotech Taiwan Co. Ltd. maintains a focused presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action currently active. This matter is assigned to 1 distinct examiner, which suggests a singular focus for the company's current intellectual property efforts. The portfolio is also confined to 1 distinct art unit, indicating that the technology being patented falls within a specific technical niche. This concentration allows for a streamlined interaction with the USPTO's examination staff and a consistent application of legal arguments across the active portfolio.
The busiest examiner for Mello Biotech Taiwan Co. Ltd. is GIBBS, TERRA C, who is responsible for the 1 busiest examiner pending action. Because this is the only active matter, GIBBS, TERRA C handles the entirety of the company's current prosecution workload. For practitioners, this means that the outcome of the pending application is dependent on the specific standards and preferences of this examiner. The alignment of 1 distinct examiner and 1 distinct art unit reflects a highly centralized strategy for securing patent rights. Success in this matter requires a deep understanding of the specific examination patterns of GIBBS, TERRA C.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18502115 | CATIONIC LIPIDS AND USES THEREOF | GIBBS, TERRA C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18502115 | CATIONIC LIPIDS AND USES THEREOF | GIBBS, TERRA C | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18502115 | CATIONIC LIPIDS AND USES THEREOF | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Nov 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial